| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Valantine Hannah | Director | C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO | /s/ Hannah A. Valantine, M.D. | 30 Jun 2025 | 0001855608 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BBIO | Common Stock | Sale | $38,640 | -876 | -8.9% | $44.11 | 9,007 | 26 Jun 2025 | Direct | F1 |
| transaction | BBIO | Common Stock | Sale | $67,863 | -1,542 | -17% | $44.01 | 7,465 | 26 Jun 2025 | Direct | |
| transaction | BBIO | Common Stock | Sale | $17,562 | -398 | -15% | $44.13 | 2,289 | 26 Jun 2025 | By Spouse | F2 |
| transaction | BBIO | Common Stock | Sale | $83,261 | -1,891 | -83% | $44.03 | 398 | 26 Jun 2025 | By Spouse |
| Id | Content |
|---|---|
| F1 | Represents the weighted average sale price of the shares sold from $44.025 to $44.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| F2 | Represents the weighted average sale price of the shares sold from $44.12 to $44.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |